Filing summary
Identity and period mismatch: The supplied text is MEI Pharma, Inc.’s Form 10-Q for the three months ended September 30, 2014 (its fiscal first quarter of 2015), not a filing for Lite Strategy, Inc. or 2013 Q1. The summary below reflects the supplied filing.
Business context and reporting period
MEI Pharma is a clinical-stage oncology company with no revenue. Its lead candidate, Pracinostat, was in Phase II trials; ME-344 was in a Phase Ib trial; and the company expected to complete preclinical work for PWT143 to support an IND filing by the end of calendar 2014.
Financial results and liquidity
| Metric | Three months ended Sep. 30, 2014 | Prior-year quarter |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $6.566 million | $3.102 million |
| General and administrative expense | $2.439 million | $1.811 million |
| Total operating expenses / operating loss | $9.005 million | $4.913 million |
| Net loss | $8.993 million | $4.896 million |
| Basic and diluted loss per share | $0.42 | $0.29 |
| Cash used in operating activities | $6.731 million | $4.063 million |
At September 30, 2014, cash, cash equivalents and short-term investments totaled $42.062 million, down from $48.793 million at June 30, 2014. Total current liabilities were $5.308 million; the balance sheet reports no debt. Accumulated deficit was $132.438 million. Gross and operating margins are not meaningful because the company reported no revenue.
Management believed available cash and investments would fund operations through calendar 2015, while anticipating a need for future capital transactions or strategic partnerships. No financing cash flows were reported in either quarter shown.
Material changes and outlook
- Net loss widened by $4.097 million year over year, principally as R&D expense rose $3.464 million. Management attributed the increase mainly to Pracinostat manufacturing and Phase II trial costs, ME-344 Phase Ib costs, and increased staffing and compensation.
- G&A expense increased $0.628 million, primarily from higher salaries, benefits, and share-based compensation.
- Operating cash use increased $2.668 million year over year. Investing activities provided $9.995 million, primarily from maturities of short-term U.S. government securities.
- Pracinostat’s randomized Phase II MDS trial had completed enrollment at 108 patients; the company expected to unblind after six months’ follow-up and report topline data in calendar Q1 2015. Additional data from an AML study were expected at the December 2014 ASH meeting.
- For ME-344, the first patient entered the cohort-expansion stage of the combination study in October 2014; the company planned to enroll 40 additional patients in small-cell lung cancer and ovarian cancer cohorts.
- The company expected to complete PWT143 preclinical work for an IND filing by year-end 2014. These are forward-looking plans, not assured outcomes.
Risks, contingencies, and unusual items
- The company expected continued operating losses and negative operating cash flows. It identified financing availability, clinical-trial outcomes and delays, regulatory approvals, commercialization, competition, manufacturing costs, and intellectual-property rights among its risks.
- The S*Bio asset agreement provides for potential clinical, regulatory, and sales milestones of up to $75.2 million in aggregate, plus contingent earnouts. No potential future payments were accrued at September 30, 2014. The first Phase III or pivotal-trial dosing milestone includes $200,000 cash and $500,000 in company shares.
- Clinical and consulting contracts are generally terminable but require reimbursement for costs incurred. The office lease covered approximately 8,800 square feet and ran through June 2015.
- The filing reported no legal proceedings and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer and period: the supplied document identifies MEI Pharma, Inc. and the quarter ended September 30, 2014, not Lite Strategy or 2013 Q1.
- Track cash burn and financing needs against management’s stated runway through calendar 2015.
- Verify timing and results of the Pracinostat trials, ME-344 expansion, and planned PWT143 IND filing.
- Assess potential dilution and obligations from equity compensation, outstanding warrants, and S*Bio milestone terms.